The mode of action of many drugs in clinical
use for the treatment of cancer, genetic
disorders and viral diseases is essentially
based on their binding to DNA and the
subsequent modifications of the genetic
material (Hurley et al., 1996; Rezler et al.,
2003; Hurley, 2001 and 2002). Therefore,
interest in understanding the interaction of
small molecule ligands with DNA sequences
has been the subject of intense investigations
for almost half a century (Waring, 1981)
(Chaires, 1998) (Maiti and Kumar, 2007).
Despite a large number of DNA binding drugs
currently in use in clinics for cancer treatment,
selectivity towards malignant cells remains an
elusive goal. More detailed knowledge and
deeper insights of the DNA interaction ....